RxDoctor Payments Data

Rachel Achenbach, OD

Optometrist · Windham, MENPI 1528408622

Payments from drug & device makers

What this record shows

Coopervision Inc. accounts for 68.9% of it on its own, with 8 other manufacturers making up the rest. 2025 is the largest year on record at $2,066, more than ten times the $40 reported in 2019. Among optometrist clinicians in ME with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$3,034in general payments, 2019–2025

Across 41 payments — averaging $74.00 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Coopervision Inc.$2K
  • Alcon$372
  • AbbVie$173
  • Bausch & Lomb, A Division Of Bausch Health US, LLC$160
  • Oyster Point Pharma, Inc.$70
  • Johnson & Johnson Vision Care, Inc.$62
  • plus $106 from 3 others

What the payments were for

  • Travel & lodging$1,63154%
  • Food & beverage$1,40346%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,034 in reported general payments places this provider in the 95th percentile of 224 optometrist providers in Maine.

See all optometrist providers in Maine

Medicare billing

Part B allowed, 2024
$24,499
Medicare patients
140
Services billed
1,481

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RestasisCyclosporine37$49,160
Latanoprost82$1,376
Brimonidine Tartrate18$1,009
Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat19$257
Neomycin-Polymyxin-DexamethNeomycin/Polymyxin B/Dexametha11$116
Timolol Maleate16$114

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieRestasis$173$49,16037 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 224 optometrist providers in Maine.

Other optometrist in Windham

See the full list for Maine

Where these figures come from

Is this you, or does something look wrong? →